ClinicalTrials.gg
Status unknownNCT04197427Updated Dec 17, 2019

Determination of the Safety and Efficacy of a Novel Oral Rinse on Oral Health

An interventional study of Experimental Oral Rinse and Placebo in Plaque and Gingivitis, sponsored by You First Services. Status unknown at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by You First Services · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Since over 50% of the US population have gingivitis, mouthrinses serve as a valuable adjunct to brushing and flossing. The primary objective is to determine the effectiveness of the oral rinse in reducing plaque and gingivitis and improve a patient's breath

Read the detailed description

This clinical study design is a randomized, double-blind, single-treatment, parallel design with a placebo as the control. Following a screening exam, the duration of the trial will be 1 month. Oral examinations will occur at Visit 1 (baseline), and Visit 2 (4 weeks post screening). Also, at these visits, subjects will be asked keep a diary for the one month and their thoughts about the effect of the mouthrinse on their breath and their mouth feeling of "freshness". They will also be asked about the taste and consistency of the mouth rinse. Plaque accumulation will be measured by the Turesky modification of the Quigley-Hein method of quantifying plaque formulation (PI). Gingival health will be measured using the Modified Gingival Index (MGI)

02

Conditions studied

  • Plaque
  • Gingivitis

Browse trials for

03

In context

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

This study's planned enrollment of 62 is close to the median of 66 across 507 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

You First Services is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has read, signed and received a copy of the and HIPAA authorization prior to study initiation.
  • Subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified study examinations.
  • Subject is between the ages of 18 and 75 years inclusive.
  • Subject will not have professional cleaning during the study.
  • Subject has no history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test drug, as determined by the Principal Investigator.
  • Subject has a minimum of 12 natural teeth.
  • Subject agrees to refrain from the use of any oral rinse, toothpaste or dentifrice other than the Aim® Fluoride toothpaste and study rinse provided on Visit 1 for the duration of the study.
  • Subject agrees to refrain from the use of other oral care products not supplied by the study center
  • Subject agrees to be compliant with study procedures.
  • Females of agree to use an adequate method of and agree to pregnancy

Exclusion criteria

Exclusion Criteria:

  • Subject has read, signed and received a copy of the and HIPAA authorization prior to study initiation.
  • Subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified study examinations.
  • Subject is between the ages of 18 and 75 years inclusive.
  • Subject will not have professional cleaning during the study.
  • Subject has no history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test drug, as determined by the Principal Investigator.
  • Subject has a minimum of 12 natural teeth.
  • Subject agrees to refrain from the use of any oral rinse, toothpaste or dentifrice other than the Aim® Fluoride toothpaste and study rinse provided on Visit 1 for the duration of the study.
  • Subject agrees to refrain from the use of other oral care products not supplied by the study center
  • Subject agrees to be compliant with study procedures.
  • Females of agree to use an adequate method of and agree to pregnancy testing at the first and second visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Experimental Oral Rinse

    In this arm the test article,oral rinse, a proprietary formulation of agents including xylitol, Caffeine, Essential oils, Monk fruit extract, which can reduce the plaque formation Subjects rinse twice a day with 10 mL of the oral rinse for 2 minutes for 30 days. They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing.

    Device: Experimental Oral Rinse

  • Placebo comparator
    Placebo Oral Rinse

    This arm will use a placebo with out the active ingredients same way the experimental arm do.

    Device: Placebo

Interventions

  • DeviceExperimental Oral Rinse

    Experimental Oral Rinse is a proprietary formulation of GRAS ingredients

  • DevicePlacebo

    Placebo formulation without the active ingredients

06

What researchers measure

Primary outcomes

  1. Effectiveness of the oral rinse in reducing plaque

    Plaque accumulation will be measured by the Turesky modification of the Quigley-Hein method of quantifying plaque formulation (PI).

    Time frame: 4 weeks

  2. Effectiveness of the oral rinse in reducing gingivitis

    Gingival health will be measured using the Modified Gingival Index (MGI)

    Time frame: 4 weeks

  3. Effectiveness of the oral rinse in improving a patient's breath

    Subjects will be asked keep a diary for one month and their thoughts about the effect of the mouthrinse on their breath and their mouth feeling of "freshness",

    Time frame: 4 weeks

Secondary outcomes

  1. Safety evaluation of the test Oral Rinse

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 4 weeks

07

Study locations

1 site
  • Department of Periodontics and Endodontics,School of Dental Medicine, University at Buffalo, SUNY
    Buffalo, New York 14214, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2020; primary completion for Nov 2020, 8 months later.

Of 53 industry-sponsored interventional studies with no phase under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 5. This study's planned 8 months is above that.

Counting every sponsor, half of 257 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Dec 13, 2019
StartEst.
Mar 1, 2020
Primary completionEst.
Nov 30, 2020
CompletionEst.
Dec 31, 2020
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04197427
Lead sponsor
You First Services
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Mar 1, 2020 (estimated)
Primary completion
Nov 30, 2020 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Dec 17, 2019

Study contacts

Sebastian Ciancio, D.D.S
Contact
ciancio@buffalo.ed
716-829-3848

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion